Immune cell therapy plus drug shows promise for advanced melanoma
NCT ID NCT01701674
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 25 times
Summary
This pilot study tested a new treatment for advanced melanoma that has spread. It combined immune cells grown from the patient's own tumor (TILs) with an immunotherapy drug called ipilimumab. The goal was to see if this combination was safe and possible to give. 13 people took part, and the study looked at side effects and how many could complete the treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.